BECTON DICKINSON & CO vs BOSTON SCIENTIFIC CORP, two Medical Devices stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where BDX and BSX diverge most: on fcf yield, BDX reads -0.3% and BSX reads 5.0%; on debt / equity, BDX reads 0.72 and BSX reads 0.00. The rest of the comparable metrics sit closer together. On valuation, today's BDX price has a different growth bar priced in than BSX (+7.7% implied for BDX vs +8.9% for BSX); the higher figure is the steeper assumption to clear, not a better or worse stock. What BDX's price implies is a bet that sits within the historical range (whole-company basis). What BSX's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | BDX | BSX |
|---|---|---|
| Price | $165.67 | $46.73 |
| Market cap | $46.5B | $69.9B |
| Sector | Medical Devices | Medical Devices |
| Stage | Mature | Growth |
| Implied growth (priced in) | +7.7% | +8.9% |
| P/E | 42.0 | 19.6 |
| P/B | 1.93 | 2.68 |
| P/S | 2.18 | 3.39 |
| EV/EBITDA | 18.5 | 13.2 |
| Revenue growth | +6.4% | +17.6% |
| Gross margin | — | 69.5% |
| Operating margin | 2.0% | 21.2% |
| Net margin | 5.3% | 17.3% |
| Return on equity | 4.7% | 13.6% |
| Return on assets | 2.2% | 8.0% |
| Return on invested capital | 4.2% | 11.5% |
| FCF yield | -0.3% | 5.0% |
| Dividend yield | 2.5% | — |
| Debt / equity | 0.72 | 0.00 |
| Current ratio | 0.94 | 1.90 |
| Altman Z (solvency) | 6.89 | 6.88 |
| Piotroski F (quality) | 5 / 9 | 5 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.